Table 3.
Changes From Baseline to Day 90 in Efficacy Outcome Measures
| Outcome Measure | Mean (SD) |
Treatment Effect for Latrepirdine vs Placebo (95% Confidence Interval)a | P Value | |
|---|---|---|---|---|
| Latrepirdine | Placebo | |||
| UHDRS | ||||
| Verbal fluencyb | 3.78 (1.04) | 4.75 (1.06) | –1.98 (–4.94 to 0.98) | .19 |
| Symbol digit modalities testb | 1.06 (0.71) | –0.14 (0.72) | 1.20 (–0.82 to 3.22) | .24 |
| Stroop color namingb | 0.44 (1.16) | 0.58 (1.16) | –0.14 (–3.42 to 3.13) | .93 |
| Stroop word readingb | –1.36 (1.53) | –3.04 (1.54) | 1.68 (–2.64 to 6.00) | .44 |
| Stroop interferenceb | –0.63 (0.97) | 0.75 (0.98) | –1.38 (–4.13 to 1.38) | .32 |
| Behavioral frequencyc | –0.86 (0.54) | 0.04 (0.56) | –0.90 (–2.44 to 0.65) | .25 |
| Behavioral frequency × severityc | –1.47 (1.26) | 0.55 (1.29) | –2.02 (–5.60 to 1.57) | .27 |
| Total motorc | –0.17 (1.11) | 0.21 (1.13) | –0.39 (–3.54 to 2.76) | .81 |
| Total functional capacityb | –0.04 (0.15) | 0.01 (0.15) | –0.06 (–0.47 to 0.36) | .79 |
| Functional assessmentb | 0.01 (0.25) | 0.11 (0.26) | –0.10 (–0.82 to 0.62) | .79 |
| Independence scaleb | –0.48 (0.77) | –0.58 (0.78) | 0.10 (–2.09 to 2.29) | .93 |
| MMSEb | 0.86 (0.31) | –0.12 (0.31) | 0.97 (0.10 to 1.85) | .03d |
| ADAS-cogc | –1.15 (0.82) | –0.84 (0.83) | –0.31 (–2.64 to 2.02) | .79 |
Abbreviations: ADAS-cog, Alzheimer Disease Assessment Scale–cognitive subscale; MMSE, Mini-Mental State Examination; UHDRS, Unified Huntington's Disease Rating Scale.
a
Treatment effect is the difference (latrepirdine–placebo) between the adjusted group mean changes calculated from a repeated-measures analysis of covariance model.
b
Positive mean change indicates improvement.
c
Negative mean change indicates improvement.
d
P < .05.